Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Country:  U.S.A.
Trial Type:  Treatment
Treatment/Intervention:  hematopoietic stem cell transplantation
Results 1-25 of 197 for your search:
Start Over
Autologous Peripheral Blood Stem Cell Transplant in Treating Patients With Lymphoma
Phase: Phase III, Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT 2004-24, NCI-2010-01414, 2005LS048, UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865
Clofarabine and Cytarabine or Standard Induction Therapy and Chemotherapy with or without Natural Killer Cell Transplant in Treating Younger Patients with Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: AML08, NCI-2011-03659, NCT00703820
Chemotherapy or Donor Stem Cell Transplant in Treating Patients with Acute Myeloid Leukemia
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J1227, NCI-2013-01746, CIR00000621, NA_00071844, NA_00071844 / CR00001237, NCT01588951
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 3
Trial IDs: ACNS0334, NCI-2009-00338, CDR0000483683, COG-ACNS0334, NCT00336024
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma
Phase: Phase III
Type: Treatment
Age: 10 and under
Trial IDs: ARET0321, NCI-2009-00421, CDR0000573987, COG-ARET0321, NCT00554788
Azacitidine in Preventing Relapse in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant
Phase: Phase III
Type: Treatment
Age: 18 to 75
Trial IDs: 2008-0503, NCI-2012-01259, NCI-2009-01513, NCT00887068
TK008: Efficacy Study on the Strategy of Herpes Simplex Virus Thymidine Kinase (HSV-Tk) Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TK008, NCI-2011-03649, 2009-012973-37, NCT00914628
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: E2906, NCI-2011-01992, CDR0000659585, ECOG-E2906, NCT01041703
Graft-Versus-Host Disease Prophylaxis in Treating Patients with Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: not specified
Trial IDs: 2448.00, NCI-2010-02035, NCT01231412
Bortezomib and Sorafenib Tosylate in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 30
Trial IDs: AAML1031, NCI-2011-02670, CDR0000701850, COG-AAML1031, NCT01371981
Melphalan with or without Busulfan before Stem Cell Transplant in Treating Patients with Multiple Myeloma
Phase: Phase III
Type: Treatment
Age: 18 to 70
Trial IDs: 2010-0071, NCI-2011-02760, cs2010-0032635MA, NCT01413178
Double Cord Versus Haploidentical (BMT CTN 1101)
Phase: Phase III
Type: Treatment
Age: 18 to 70
Trial IDs: BMTCTN1101, NCI-2014-00307, 2U10HL069294-11, 715, NCT01597778
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine with or without Vorinostat in Treating Younger Patients with Previously Untreated Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 15 to 60
Trial IDs: S1203, NCI-2013-00490, PS1203_A06PAMDREVW01, SWOG-S1203, NCT01802333
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
Phase: Phase III
Type: Treatment
Age: 65 and under
Trial IDs: CB-AB006, NCI-2013-00758, 2012-0166, NCT01854567
Combination Chemotherapy with or without Blinatumomab in Treating Patients with Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Age: 35 to 70
Trial IDs: E1910, NCI-2013-02229, ECOG-E1910, PE1910_A08PAMDREVW01, NCT02003222
Blinatumomab in Treating Younger Patients with Relapsed B-cell Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 30
Trial IDs: AALL1331, NCI-2014-00631, COG-AALL1331, NCT02101853
Combination Chemotherapy or 90-Yttrium Ibritumomab Tiuxetan and Combination Chemotherapy before Stem Cell Transplant in Treating Patients with Relapsed Diffuse Large B-cell Non-Hodgkin Lymphoma
Phase: Phase III
Type: Treatment
Age: 18 to 70
Trial IDs: 12338, NCI-2015-00185, 093270, 2012-0005534-11, NCT00491491, NCT02366663
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
Phase: Phase III
Type: Treatment
Age: 14 and over
Trial IDs: A031102, NCI-2014-01696, PA031102_A01PAMDREVW01, NCT02375204
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients with Relapsed or Refractory Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 65 and under
Trial IDs: 1409.00, NCI-2010-00130, FHCRC-1409.00, 4903, NCI-G00-1776, NCT00005803
Alemtuzumab Before Donor Stem Cell Transplant in Treating Patients With Hematologic Diseases
Phase: Phase II, Phase I
Type: Treatment
Age: 70 and under
Trial IDs: HIMSUM, NCI-2012-00639, NCT00058825
Vaccine Therapy, Rituximab, Peripheral Blood Stem Cell Transplant, and Therapeutic Autologous Lymphocytes in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: LYMNHL0040-BMT212, NCI-2011-00136, 5089, 96940, NCT00490529
Donor Umbilical Cord Blood Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 1 to 70
Trial IDs: 2005-0781, NCI-2011-02823, RP100469 02, NCT00498316
Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning for Patients with Severe Systemic Sclerosis
Phase: Phase II, Phase I
Type: Treatment
Age: 17 to 70
Trial IDs: 2067.00, NCI-2011-01352, FHCRC-2067.00, 6364, NCT00622895
Start Over